ORMP · Categories · Form 4

ORMP - SEC Form 4 insider transactions

Oramed Pharmaceuticals Inc. (ORMP) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ORMP

• 69d
  SEC Form 4 filed by Kidron Nadav

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 69d
  SEC Form 4 filed by Kidron Miriam

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 81d
  SEC Form 4 filed by Gabay Avraham

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 81d
  SEC Form 4 filed by Hexter Joshua

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 81d
  SEC Form 4 filed by Kidron Miriam

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 81d
  SEC Form 4 filed by Kidron Nadav

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 84d
  President and CEO Kidron Nadav gifted 100,000 shares, decreasing direct ownership by 3% to 3,255,238 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 129d
  President and CEO Kidron Nadav converted options into 109,000 shares, increasing direct ownership by 3% to 3,355,238 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 129d
  Chief Financial Officer Gabay Avraham converted options into 19,000 shares, increasing direct ownership by 3% to 649,256 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 129d
  Chief Scientific Officer Kidron Miriam converted options into 19,000 shares, increasing direct ownership by 1% to 1,448,664 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 129d
  COO & CBO Hexter Joshua converted options into 19,000 shares, increasing direct ownership by 2% to 1,064,495 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 137d
  Chief Scientific Officer Kidron Miriam gifted 86,166 shares, decreasing direct ownership by 6% to 1,343,498 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  Director Reznick Yehuda was granted 36,250 shares, increasing direct ownership by 53% to 105,180 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  President and CEO Kidron Nadav was granted 559,640 shares, increasing direct ownership by 21% to 3,246,238 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  Chief Scientific Officer Kidron Miriam was granted 236,331 shares, increasing direct ownership by 20% to 1,429,664 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  COO & CBO Hexter Joshua was granted 212,328 shares, increasing direct ownership by 25% to 1,045,495 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  Director Shapiro Benjamin was granted 33,500 shares, increasing direct ownership by 37% to 123,220 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 153d
  Director Mayer Arie was granted 34,900 shares, increasing direct ownership by 26% to 168,009 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 156d
  Director Aghion Daniel was granted 36,250 shares, increasing direct ownership by 47% to 113,441 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 156d
  Chief Financial Officer Gabay Avraham was granted 196,216 shares, increasing direct ownership by 45% to 630,256 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 364d
  Director Mayer Arie was granted 36,975 shares, increasing direct ownership by 38% to 133,109 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 364d
  Director Aghion Daniel was granted 38,371 shares, increasing direct ownership by 99% to 77,191 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 364d
  Director Reznick Yehuda was granted 38,370 shares, increasing direct ownership by 126% to 68,930 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 364d
  Director Sank Leonard was granted 36,510 shares, increasing direct ownership by 37% to 134,531 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 364d
  Director Shapiro Benjamin was granted 34,650 shares, increasing direct ownership by 63% to 89,720 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 481d
  Chief Scientific Officer Kidron Miriam was granted 192,667 shares, increasing direct ownership by 19% to 1,193,333 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 481d
  COO & CBO Hexter Joshua was granted 126,834 shares, increasing direct ownership by 18% to 833,167 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 481d
  President and CEO Kidron Nadav was granted 427,000 shares, increasing direct ownership by 19% to 2,686,598 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 481d
  Chief Financial Officer Gabay Avraham was granted 76,000 shares, increasing direct ownership by 21% to 434,040 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 517d
  President and CEO Kidron Nadav was granted 433,500 shares, increasing direct ownership by 24% to 2,259,598 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 517d
  Chief Financial Officer Gabay Avraham was granted 188,000 shares, increasing direct ownership by 111% to 358,040 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 517d
  COO & CBO Hexter Joshua was granted 194,500 shares, increasing direct ownership by 38% to 706,333 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 517d
  Chief Scientific Officer Kidron Miriam was granted 207,000 shares, increasing direct ownership by 26% to 1,000,666 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 576d
  COO & CBO Hexter Joshua was granted 30,000 shares, increasing direct ownership by 6% to 511,833 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 576d
  President and CEO Kidron Nadav was granted 45,000 shares, increasing direct ownership by 3% to 1,826,098 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 576d
  Chief Financial Officer Gabay Avraham was granted 30,000 shares, increasing direct ownership by 21% to 170,040 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 576d
  Chief Scientific Officer Kidron Miriam was granted 30,000 shares, increasing direct ownership by 4% to 793,666 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 717d
  Chief Financial Officer Gabay Avraham was granted 140,040 shares (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 727d
  Director Reznick Yehuda was granted 760 shares, increasing direct ownership by 3% to 30,560 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 780d
  Reznick Yehuda was granted 29,800 shares (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 859d
  Aghion Daniel was granted 3,750 shares, increasing direct ownership by 11% to 38,820 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Kidron Miriam was granted 295,500 shares, increasing direct ownership by 63% to 763,666 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Kidron Nadav was granted 329,000 shares, increasing direct ownership by 23% to 1,781,098 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Hexter Joshua was granted 180,500 shares, increasing direct ownership by 60% to 481,833 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Silberman David was granted 136,500 shares, increasing direct ownership by 59% to 366,500 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Sank Leonard was granted 39,325 shares, increasing direct ownership by 67% to 98,021 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Rozov Yadin was granted 38,820 shares, increasing direct ownership by 33% to 155,320 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Mayer Arie was granted 39,325 shares, increasing direct ownership by 69% to 96,134 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Aghion Daniel was granted 35,070 shares (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 881d
  Shapiro Benjamin was granted 35,070 shares, increasing direct ownership by 175% to 55,070 units (SEC Form 4)

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1103d
  SEC Form 4 filed by Derovan Netanel

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1103d
  SEC Form 4 filed by Kidron Miriam

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1103d
  SEC Form 4 filed by Kidron Nadav

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1103d
  SEC Form 4 filed by Hexter Joshua

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1103d
  SEC Form 4 filed by Silberman David

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1133d
  SEC Form 4 filed by Shapiro Benjamin

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1145d
  SEC Form 4 filed by Derovan Netanel

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1145d
  SEC Form 4 filed by Kidron Miriam

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1145d
  SEC Form 4 filed by Sank Leonard

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
• 1145d
  SEC Form 4 filed by Rozov Yadin

  4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

Other ORMP categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends